BR112017015614A2 - produtos terapêuticos de glicano e métodos relacionados dos mesmos. - Google Patents

produtos terapêuticos de glicano e métodos relacionados dos mesmos.

Info

Publication number
BR112017015614A2
BR112017015614A2 BR112017015614A BR112017015614A BR112017015614A2 BR 112017015614 A2 BR112017015614 A2 BR 112017015614A2 BR 112017015614 A BR112017015614 A BR 112017015614A BR 112017015614 A BR112017015614 A BR 112017015614A BR 112017015614 A2 BR112017015614 A2 BR 112017015614A2
Authority
BR
Brazil
Prior art keywords
related methods
therapeutic glycan
glycan products
products
therapeutic
Prior art date
Application number
BR112017015614A
Other languages
English (en)
Other versions
BR112017015614B1 (pt
Inventor
A Von Maltzahn Geoffrey
Milwid Jack
Silverman Jared
M Geremia John
J Yamanaka Yvonne
Original Assignee
Kaleido Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaleido Biosciences Inc filed Critical Kaleido Biosciences Inc
Publication of BR112017015614A2 publication Critical patent/BR112017015614A2/pt
Publication of BR112017015614B1 publication Critical patent/BR112017015614B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
BR112017015614-8A 2015-01-26 2016-01-13 Composições farmacêuticas e seus métodos de produção, usos de uma preparação terapêutica de glicano e kit farmacêutico BR112017015614B1 (pt)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US201562108039P 2015-01-26 2015-01-26
US201562152016P 2015-04-23 2015-04-23
US201562152007P 2015-04-23 2015-04-23
US201562152005P 2015-04-23 2015-04-23
US201562152017P 2015-04-23 2015-04-23
US201562152011P 2015-04-23 2015-04-23
US201562216993P 2015-09-10 2015-09-10
US201562216995P 2015-09-10 2015-09-10
US201562216997P 2015-09-10 2015-09-10
US201562217002P 2015-09-10 2015-09-10
US62/216,997 2015-09-10
US62/216,993 2015-09-10
US62/216,995 2015-09-10
US201562238112P 2015-10-06 2015-10-06
US201562238110P 2015-10-06 2015-10-06
US62/238,110 2015-10-06
US62/238,112 2015-10-06
PCT/US2016/013305 WO2016122889A1 (en) 2015-01-26 2016-01-13 Glycan therapeutics and related methods thereof

Publications (2)

Publication Number Publication Date
BR112017015614A2 true BR112017015614A2 (pt) 2018-04-10
BR112017015614B1 BR112017015614B1 (pt) 2023-05-09

Family

ID=55349947

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017015614-8A BR112017015614B1 (pt) 2015-01-26 2016-01-13 Composições farmacêuticas e seus métodos de produção, usos de uma preparação terapêutica de glicano e kit farmacêutico

Country Status (23)

Country Link
US (6) US20170151268A1 (pt)
EP (3) EP3354282B1 (pt)
JP (3) JP2018502926A (pt)
KR (1) KR20170122753A (pt)
CN (1) CN107427528B (pt)
AU (2) AU2016212030B2 (pt)
BR (1) BR112017015614B1 (pt)
CA (1) CA2973617A1 (pt)
CL (1) CL2017001901A1 (pt)
DK (2) DK3354282T3 (pt)
EA (1) EA201791702A1 (pt)
ES (2) ES2857557T3 (pt)
IL (3) IL253195B (pt)
LT (2) LT3354282T (pt)
MX (2) MX2020001555A (pt)
MY (1) MY188879A (pt)
PH (1) PH12017501342A1 (pt)
PL (2) PL3354282T3 (pt)
PT (2) PT3071235T (pt)
SG (2) SG11201706033XA (pt)
SI (2) SI3071235T1 (pt)
WO (1) WO2016122889A1 (pt)
ZA (1) ZA201704735B (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019090180A1 (en) 2017-11-03 2019-05-09 Kaleido Biosciences, Inc. Glycan preparations for the treatment of infection
MX2017000319A (es) 2014-07-09 2017-04-27 Midori Usa Inc Composiciones oligosacaridas y metodos para produccion de estas.
BR112017015944B1 (pt) 2015-01-26 2022-03-22 Cadena Bio, Inc Composição de ração animal, pré-mistura de ração animal, uso e método para produzir uma composição de ração animal
US9492473B2 (en) * 2015-01-26 2016-11-15 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
PL3354282T3 (pl) 2015-01-26 2021-07-05 Kaleido Biosciences, Inc. Glikanowe środki terapeutyczne i związane z nimi sposoby
US20180147221A1 (en) 2015-04-23 2018-05-31 Kaleido Biosciences, Inc. Glycan therapeutic compositions and related methods thereof
CN108135925A (zh) * 2015-08-25 2018-06-08 卡莱多生物科技有限公司 聚糖组合物及其用途
WO2018013871A1 (en) 2016-07-13 2018-01-18 Kaleido Biosciences, Inc. Glycan compositions and methods of use
US11959125B2 (en) * 2016-09-15 2024-04-16 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
CN110267663A (zh) * 2016-12-06 2019-09-20 卡莱多生物科技有限公司 聚糖聚合物及其相关方法
CA3085196A1 (en) * 2016-12-23 2018-06-28 Murdoch Children's Research Institute Methods and compositions for determining, and for minimizing, the likelihood of development of allergy in infants
JP2020513014A (ja) * 2017-04-07 2020-04-30 チルドレンズ ホスピタル メディカル センター ２’−フコシルラクトース化合物による炎症性腸疾患の治療
US20230149497A1 (en) * 2017-06-02 2023-05-18 Goodgut S.L. Grape skin for use in the treatment of dysbiosis
WO2019014645A1 (en) 2017-07-13 2019-01-17 Kaleido Biosciences, Inc. GLYCAN COMPOSITIONS AND METHODS OF USE
TWI640314B (zh) * 2017-08-22 2018-11-11 長庚生物科技股份有限公司 戈氏副擬桿菌用於降低胰島素抗性及提升葡萄糖耐受性之用途
JP6967404B2 (ja) * 2017-08-31 2021-11-17 雪印メグミルク株式会社 アッカーマンシア・ムシニフィラ増加促進用組成物
US11898184B2 (en) 2017-09-07 2024-02-13 Sweet Sense Inc. Low glycemic sugar composition
US10478418B2 (en) 2017-09-13 2019-11-19 In Ingredients, Inc. Inhibited expression of PD-L1 and enhanced expression of PD-1
US10894030B2 (en) 2017-09-13 2021-01-19 In Ingredients, Inc. Methods and compositions for the inhibition of the expression of PD-L1 in tumor cells
US20200246411A1 (en) * 2017-09-29 2020-08-06 Adithya SAGAR Anti-diarrhoeal herbal compositions
US20220233577A1 (en) * 2017-11-03 2022-07-28 Kaleido Biosciences, Inc. Glycan preparations and methods of use for hyperammonemia
EP3704161A1 (en) 2017-11-03 2020-09-09 Kaleido Biosciences, Inc. Methods of producing glycan polymers
WO2019092896A1 (ja) * 2017-11-08 2019-05-16 アサヒグループホールディングス株式会社 アッカーマンシア・ムシニフィラ増殖材
KR102041916B1 (ko) * 2017-12-15 2019-11-08 (주)녹십자웰빙 신장질환 진행 억제 및 예방용 프로바이오틱스 및 이를 포함하는 신장질환 진행 억제 및 예방용 조성물
WO2019136214A1 (en) * 2018-01-05 2019-07-11 California Institute Of Technology Probiotics, metabolites, and uses thereof
CN108125975A (zh) * 2018-01-29 2018-06-08 广东省农业科学院动物卫生研究所 野漆树苷在制备抗微小隐孢子虫药物中的应用
WO2019153334A1 (zh) * 2018-02-12 2019-08-15 天津天狮生物发展有限公司 一种调节人体肠道功能的复合益生元及其应用
EP3530281A1 (en) * 2018-02-22 2019-08-28 Gnubiotics Sciences Sàrl New process of preparation of glycan compositions & uses thereof
EP3755343A1 (en) * 2018-02-22 2020-12-30 Gnubiotics Sciences SA New process of preparation of glycan composition & uses thereof
CN108760900A (zh) * 2018-03-20 2018-11-06 华南理工大学 一种测定羧甲基纤维素钠取代度的顶空气相色谱法
WO2019205942A1 (zh) * 2018-04-27 2019-10-31 美益添生物医药(武汉)有限公司 一种提高肠道中scfa产生菌的复合制剂及制备方法与应用
CN108403930B (zh) * 2018-04-27 2021-08-20 美益添生物医药(武汉)有限公司 一种提高肠道中akk菌/致病菌比值的复合制剂及制备方法与应用
CN108567901B (zh) * 2018-04-27 2021-07-23 美益添生物医药(武汉)有限公司 一种提高肠道中scfa产生菌的复合制剂及制备方法与应用
JP7195067B2 (ja) * 2018-06-20 2022-12-23 花王株式会社 ロズマリン酸誘導体又はその塩
AU2019306649A1 (en) * 2018-07-19 2021-02-04 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
WO2020033796A1 (en) * 2018-08-10 2020-02-13 Metagenics, Inc. Method of treating inflammatory bowel disease
US11918602B2 (en) 2018-08-10 2024-03-05 Simeon Investment, Inc. Methods for reducing cholesterol with superabsorbent materials
US11925660B2 (en) 2018-08-10 2024-03-12 Simeon Investment, Inc. Treatment for obesity with superabsorbent materials
JP7223477B2 (ja) * 2018-10-10 2023-02-16 花王株式会社 Ｔｒｐｖ４活性抑制剤
MX2021005245A (es) 2018-11-08 2021-06-18 Kaleido Biosciences Inc Composiciones de oligosacaridos y metodos de uso de las mismas.
KR102196047B1 (ko) * 2018-11-14 2020-12-29 건국대학교 글로컬산학협력단 메타중아황산염을 포함하는 사료 원료 보존용 조성물 및 이를 이용한 사료의 제조방법
TWI692777B (zh) * 2018-11-16 2020-05-01 長庚醫療財團法人高雄長庚紀念醫院 智能化急性腎損傷藥物警示系統
ES2945216T3 (es) * 2018-11-26 2023-06-29 Purac Biochem Bv Composición de conservante alimentario particulada
ES2763874B2 (es) * 2018-11-30 2020-10-13 Consejo Superior Investigacion Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades
CN109633011A (zh) * 2018-12-29 2019-04-16 中山百灵生物技术有限公司 一种新的甘氨酸含量的检测方法
US20220104528A1 (en) 2019-01-31 2022-04-07 Gnubiotics Sciences Sa Compositions derived from gastrointestinal tract mucins
US11788155B1 (en) * 2019-06-06 2023-10-17 University Of South Florida Lung microbiome isolation and cultivation
CN110115713A (zh) * 2019-06-20 2019-08-13 郑州康金瑞健康产业有限公司 一种止鼾液及其制备方法
WO2021016083A1 (en) * 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders
US20210070890A1 (en) * 2019-09-06 2021-03-11 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
WO2021067167A1 (en) * 2019-10-03 2021-04-08 The Regents Of The University Of Michigan Clostrodioides difficile treatment
EP4049667A4 (en) * 2019-10-21 2024-02-21 Biofermin Pharmaceutical Co Ltd AGENT FOR REDUCING UREMIC TOXINS
KR102470108B1 (ko) * 2020-01-02 2022-11-23 삼육대학교산학협력단 부티리시모나스 속 균주를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 조성물
KR102470116B1 (ko) * 2020-01-02 2022-11-23 삼육대학교산학협력단 부티리시모나스 속 균주를 유효성분으로 포함하는 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
US20210345634A1 (en) * 2020-05-07 2021-11-11 Christopher Burns Dissolving coffee beads
BR112022024217A2 (pt) * 2020-05-29 2023-01-24 Cargill Inc Composição de oligossacarídeo de glicose, ração para animais ou produto de ração para animais de estimação, utilização da composição de oligossacáridos de glucose, e, processo para a fabricação de uma composição
JP2023534047A (ja) * 2020-07-17 2023-08-07 ディーエスエム・ニュートリショナル・プロダクツ・エルエルシー オリゴ糖組成物及び使用方法
CN111671911B (zh) * 2020-07-24 2021-08-10 刘艳 一种治疗盆底失驰缓型便秘的药物组合物及其制备方法
CN111999411B (zh) * 2020-09-01 2022-08-09 山东省农业科学院农业质量标准与检测技术研究所 果蔬中矢车菊素及3种花色苷的高效液相色谱检测方法
JP2022092966A (ja) * 2020-12-11 2022-06-23 トヨタ自動車株式会社 ジペプチジルペプチダーゼｉｖ阻害剤、機能性表示食品
KR102294437B1 (ko) * 2021-02-17 2021-08-27 주식회사 메디오젠 영유아 유래 유산균 락토바실러스 플란타럼 mg4553 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물
KR102294442B1 (ko) * 2021-02-17 2021-08-27 주식회사 메디오젠 영유아 유래 유산균 락토바실러스 플란타럼 mg4555 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물
CN113073066B (zh) * 2021-04-16 2022-01-04 段云峰 罗伊氏乳杆菌及其应用、组合物、药物和食品
CN113430242B (zh) * 2021-07-07 2022-02-18 北京浩鼎瑞生物科技有限公司 一种筛选对肠道微生态具有促进作用的提取物方法及将其用于靶向筛选益生菌的应用
WO2023009457A1 (en) * 2021-07-26 2023-02-02 Ahmed Suzanne Drug delivery platform for delivery of therapeutics and methods of use and manufacture thereof
RU2770882C1 (ru) * 2021-08-23 2022-04-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Белгородский государственный аграрный университет имени В.Я. Горина" Способ получения хлорофиллсодержащего продукта в качестве пищевого красителя
CN113797183B (zh) * 2021-11-05 2022-08-19 安徽医科大学第一附属医院 五味子酚在制备防治霉酚酸所致腹泻药物中的应用
CN114166961B (zh) * 2021-11-17 2022-11-22 西南大学 一种测定柑桔汁产品中酚类化合物及其前处理的方法
CN114376939B (zh) * 2021-12-27 2023-08-25 广州丸美生物科技有限公司 一种多糖组合物及其制备方法与应用
KR20230147547A (ko) * 2022-04-13 2023-10-23 블루스톤 파르마 게엠베하 프로바이오틱스 및 이소말툴로스를 포함하는 생성물 및 이의 생산 방법
CN117815443A (zh) * 2024-03-05 2024-04-05 江苏宝众宝达药业股份有限公司 一种保护透析血管通路的外用敷料及其制备方法

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2027904A (en) 1933-02-16 1936-01-14 Int Suiker En Alcohol Cie Inte Method of polymerizing monosaccharides
US2436967A (en) 1942-04-01 1948-03-02 Corn Prod Refining Co Polymerization of sugars
US2719179A (en) 1951-01-25 1955-09-27 Mora Peter Tibor Branched-chain carbohydrate polymers and their preparation
US3766165A (en) 1966-08-17 1973-10-16 Pfizer Polysaccharides and their preparation
US3876794A (en) 1972-12-20 1975-04-08 Pfizer Dietetic foods
US3973049A (en) 1974-03-14 1976-08-03 General Foods Corporation Method of mixing flavors and fixed composition comprising derivatized synthetic polysaccharides
US4965354A (en) 1988-02-26 1990-10-23 Taito Company, Ltd. Process for producing a condensed polysaccharide
US5667593A (en) 1989-01-26 1997-09-16 Cultor Ltd. Modified polydextrose and process therefor
TW203106B (pt) 1991-07-18 1993-04-01 Textilma Ag
JPH06121693A (ja) 1992-08-25 1994-05-06 Akebono Brake Res & Dev Center Ltd 高重合度オリゴ糖の製造法
FR2697023B1 (fr) 1992-10-16 1994-12-30 Roquette Freres Polymère soluble hypocalorique du glucose et procédé de préparation de ce polymère .
US5843922A (en) 1994-07-29 1998-12-01 Fuisz Technologies Ltd. Preparation of oligosaccharides and products therefrom
WO1998041545A1 (en) 1997-03-19 1998-09-24 Cultor Food Science, Inc. Polymerization of mono-and disaccharides using low levels of mineral acids
US6475552B1 (en) 1997-03-19 2002-11-05 Danisco Finland Oy Polymerization of mono and disaccharides using low levels of polycarboxylic acids
DE19860376A1 (de) 1998-12-28 2000-07-06 Aventis Res & Tech Gmbh & Co Alpha-1,4 Glucanketten enthaltende Polysaccharide sowie Verfahren zu ihrer Herstellung
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6426421B1 (en) 1999-11-24 2002-07-30 Massachusetts Institute Of Technology Protecting groups useful in the synthesis of polysaccharides, natural products, and combinatorial libraries
US7608291B2 (en) 2000-03-10 2009-10-27 Mars, Inc. Treatment of infection in animals
CN100438779C (zh) 2000-12-27 2008-12-03 努特里奇亚有限公司 具有健康促进作用的含有寡糖的营养组合物
DE10147100A1 (de) * 2001-09-25 2003-04-17 Numico Res B V Antiinfektive Kohlenhydrate
NZ515869A (en) 2001-11-30 2003-09-26 Med Chem Ingredients Ltd Compositions and methods for animal treatment comprising gluco- and isomalto- oligosaccharides
DE50305049D1 (de) 2002-06-07 2006-10-26 Suedzucker Ag Galactosyl-isomalt, verfahren zu seiner herstellung und verwendung
EP2272522B1 (en) 2002-06-28 2017-09-06 Nestec S.A. Therapeutic compositions for use in prophylaxis or treatment of diarrheas
JP2005533525A (ja) 2002-07-23 2005-11-10 ニオズ テクノロジーズ インコーポレイテッド 細菌グリコシルトランスフェラーゼを用いたオリゴ糖、糖脂質、及び糖タンパク質の合成
WO2004018645A2 (en) 2002-08-23 2004-03-04 E.I. Du Pont De Nemours And Company Utilization of starch products for biological production by fermentation
US20040052915A1 (en) 2002-09-13 2004-03-18 Carlson Ting L. Use of low glycemic index sweeteners in food and beverage compositions
FI20021772A (fi) 2002-10-04 2004-04-05 Biotie Therapies Oyj Uudet hiilihydraattikoostumukset ja menetelmä niiden valmistamiseksi
GB0229015D0 (en) * 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
US7291607B2 (en) * 2003-05-20 2007-11-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Isomaltooligosaccharides from Leuconostoc as neutraceuticals
CA2520043C (en) 2003-06-30 2009-09-01 Clasado Inc. Novel galactooligosaccharide composition and the preparation thereof
EP1634599A1 (en) 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
FR2874825B1 (fr) * 2004-09-08 2006-12-08 Genibio Sarl Utilisations d'oligosaccharides prebiotiques benefiques pour la flore vaginale
US20060093592A1 (en) 2004-10-04 2006-05-04 Nutracea Synbiotics
DE102004058811A1 (de) 2004-12-07 2006-06-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Zuckeralkoholen
WO2007010084A2 (en) 2005-07-15 2007-01-25 Johannes Savolainen Immunostimulatory oligo- and polysaccharides and uses thereof
EP1919300A1 (en) 2005-07-27 2008-05-14 Cantabria Group LCC Phosphorytated glucomannan polysaccharides containing 1-6 and 1-2 linkages increase weight gain in swine
WO2007025006A1 (en) 2005-08-25 2007-03-01 Archer-Daniels-Midland Company Use of dextrin in animal feeds
CA2626398C (en) 2005-10-24 2011-04-19 Nestec S.A. Dietary fiber formulation and method of administration
US8057840B2 (en) 2006-01-25 2011-11-15 Tate & Lyle Ingredients Americas Llc Food products comprising a slowly digestible or digestion resistant carbohydrate composition
US8993039B2 (en) 2006-01-25 2015-03-31 Tate & Lyle Ingredients Americas Llc Fiber-containing carbohydrate composition
US7915235B2 (en) * 2006-03-20 2011-03-29 Brian Dieckgraefe High affinity ligands bind to clostridium difficile toxin A
US20090163427A1 (en) 2006-04-10 2009-06-25 Aleksander Vladimirovich Dikovskiy Pharmaceutical Composition of Enterosorbent and Prebiotics, Dosage Forms, and the Method for Prevention and Treatment of Gastrointestinal Disorders
EP1887017A1 (en) 2006-08-09 2008-02-13 Friesland Brands B.V. Prebiotic carbohydrate
FI20065593L (fi) 2006-09-26 2008-03-27 Valio Oy Menetelmä galakto-oligosakkarideja sisältävien tuotteiden valmistamiseksi ja niiden käyttö
US20130216693A1 (en) 2007-01-24 2013-08-22 Tate & Lyle Ingredients Americas Llc Fiber-containing carbohydrate composition
ES2304223B2 (es) 2007-03-08 2009-05-01 Universidad De Sevilla Nuevos caramelos con elevado contenido en oligosacaridos prebioticos, procedimiento de preparacion y utilizacion.
US8197872B2 (en) 2007-05-17 2012-06-12 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
WO2008156354A1 (en) 2007-06-21 2008-12-24 N.V. Nutricia Modulation of intestinal flora of hiv patients
PL2234505T3 (pl) * 2007-12-21 2013-06-28 Nutricia Nv Zastosowanie sfingomieliny i nietrawionych węglowodanów do poprawy mikroflory jelitowej
EP2282648A4 (en) 2008-06-09 2011-09-21 Temple Inland PREBIOTIC COMPOSITIONS AND MANUFACTURING AND USE METHOD THEREFOR
DK2355670T3 (da) 2008-12-10 2013-06-24 Univ Leuven Kath Næringsmiddel indeholdende arabinoxylan og oligosaccharider
NZ595174A (en) 2009-03-13 2013-04-26 Univ California Prebiotic galacto oligosaccharides used to stimulate growth or colonisation of beneficial bifidobacterium bacteria in gut
JP6077303B2 (ja) 2009-05-07 2017-02-08 タト エ リル アングルディアント フランス ソシエテ パ アクシオンス シンプリフィエ アルファ−（１，２）−分岐アルファ−（１，６）オリゴデキストランを含有する組成物及びアルファ−（１，２）−分岐アルファ−（１，６）オリゴデキストランの製造方法
AU2009347008B2 (en) 2009-05-27 2013-08-15 Clasado Limited Method of preventing diarrhoea
CN106890329A (zh) 2009-07-15 2017-06-27 N·V·努特里奇亚 用于刺激免疫系统的不可消化低聚糖的混合物
US8691792B2 (en) 2009-08-05 2014-04-08 Nestec Sa Methods and compositions for improving gastrointetinal health
EP2401925B1 (fr) 2010-06-29 2014-05-07 Rosebud AG Produit prebiotique et procede de fabrication
US20140187474A1 (en) 2011-02-16 2014-07-03 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic use of mucin glycans
US8466242B2 (en) 2011-02-28 2013-06-18 Midori Renewables, Inc. Polymeric acid catalysts and uses thereof
EP2707493A4 (en) 2011-05-13 2014-10-08 Glycom As PROCESS FOR THE PREPARATION OF HUMAN MILK OLIGOSACCHARIDES (HMO) OR PRECURSORS THEREOF
WO2013036726A1 (en) 2011-09-08 2013-03-14 Rutgers, The State University Of New Jersey Production of enriched products
US20150087616A1 (en) 2011-11-30 2015-03-26 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
FR2987360B1 (fr) 2012-02-28 2014-03-28 Roquette Freres Maltodextrines hyperbranchees hypo-glycemiantes
EP2666788A1 (en) 2012-05-21 2013-11-27 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO Glucan fibre
US20150202607A1 (en) 2012-08-24 2015-07-23 Midori Renewables, Inc. Polymeric and solid-supported catalysts, and methods of digesting cellulosic materials using such catalysts
CN104736245B (zh) 2012-08-24 2017-04-12 米德瑞（美国）有限公司 高分子催化剂和固载化催化剂、以及使用该催化剂消化纤维素材料的方法
US20150238948A1 (en) 2012-08-24 2015-08-27 Midori Renewables, Inc. Polymeric and solid-supported catalysts, and methods of digesting lignin-containing materials using such catalysts
US9238845B2 (en) 2012-08-24 2016-01-19 Midori Usa, Inc. Methods of producing sugars from biomass feedstocks
ES2709599T3 (es) 2013-02-21 2019-04-16 Jennewein Biotechnologie Gmbh Oligosacáridos fucosilados sintéticos o recombinantes para uso en el tratamiento de infecciones
SG11201507229QA (en) 2013-03-14 2015-10-29 Midori Usa Inc Polymeric ionic salt catalysts and methods of producing thereof
WO2014145276A1 (en) 2013-03-15 2014-09-18 Cargill, Incorporated Carbohydrate compositions
WO2015153841A1 (en) 2014-04-04 2015-10-08 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
MX2017000319A (es) 2014-07-09 2017-04-27 Midori Usa Inc Composiciones oligosacaridas y metodos para produccion de estas.
US9492473B2 (en) 2015-01-26 2016-11-15 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
CN107428789A (zh) 2015-01-26 2017-12-01 卡德纳生物股份有限公司 用于营养组合物的寡糖组合物和其制造方法
PL3354282T3 (pl) 2015-01-26 2021-07-05 Kaleido Biosciences, Inc. Glikanowe środki terapeutyczne i związane z nimi sposoby
BR112017015946A2 (pt) 2015-01-26 2018-07-10 Cadena Bio, Inc. composições de oligossacarídeo para uso como ingredientes alimentares e métodos para produzir as mesmas
BR112017015944B1 (pt) 2015-01-26 2022-03-22 Cadena Bio, Inc Composição de ração animal, pré-mistura de ração animal, uso e método para produzir uma composição de ração animal
US20180147221A1 (en) 2015-04-23 2018-05-31 Kaleido Biosciences, Inc. Glycan therapeutic compositions and related methods thereof
MX2017013562A (es) 2015-04-23 2018-05-28 Kaleido Biosciences Inc Reguladores de microbioma y usos relacionados de los mismos.
WO2017083520A1 (en) 2015-11-13 2017-05-18 Cadena Bio, Inc. Animal therapeutic and feed compositions and methods of use
US11484547B2 (en) * 2018-01-08 2022-11-01 Performance Labs PTE. LTD. Compositions and methods for cholesterol, glucose and microbiome control

Also Published As

Publication number Publication date
DK3071235T3 (en) 2018-02-19
US20170151269A1 (en) 2017-06-01
SI3354282T1 (sl) 2021-07-30
ES2857557T3 (es) 2021-09-29
US9757403B2 (en) 2017-09-12
US10702542B2 (en) 2020-07-07
CL2017001901A1 (es) 2018-07-06
PL3071235T3 (pl) 2018-05-30
WO2016122889A1 (en) 2016-08-04
AU2016212030A1 (en) 2017-07-20
US20200093851A1 (en) 2020-03-26
US10314853B2 (en) 2019-06-11
IL253195B (en) 2021-08-31
US20180147222A1 (en) 2018-05-31
US20170151268A1 (en) 2017-06-01
DK3354282T3 (da) 2021-03-08
BR112017015614B1 (pt) 2023-05-09
SG11201706033XA (en) 2017-08-30
EP3354282B1 (en) 2020-12-30
AU2021203605A1 (en) 2021-07-01
CN107427528B (zh) 2022-09-23
LT3354282T (lt) 2021-04-12
IL277342A (en) 2020-10-29
MX2020001555A (es) 2021-04-09
IL277342B (en) 2022-02-01
PL3354282T3 (pl) 2021-07-05
IL253195A0 (en) 2017-08-31
SG10202103777UA (en) 2021-05-28
MX2017009589A (es) 2018-06-20
EP3354282A1 (en) 2018-08-01
CA2973617A1 (en) 2016-08-04
IL285179A (en) 2021-08-31
MY188879A (en) 2022-01-12
SI3071235T1 (en) 2018-04-30
JP2023022175A (ja) 2023-02-14
US20210113596A1 (en) 2021-04-22
US20200093845A1 (en) 2020-03-26
LT3071235T (lt) 2018-04-25
EP3862002A1 (en) 2021-08-11
AU2016212030B2 (en) 2021-06-17
JP2018502926A (ja) 2018-02-01
US11229660B2 (en) 2022-01-25
PT3071235T (pt) 2018-02-21
PH12017501342A1 (en) 2017-12-18
EP3071235B1 (en) 2017-12-13
ZA201704735B (en) 2019-02-27
EA201791702A1 (ru) 2018-04-30
US10881676B2 (en) 2021-01-05
CN107427528A (zh) 2017-12-01
JP2021063079A (ja) 2021-04-22
KR20170122753A (ko) 2017-11-06
EP3071235A1 (en) 2016-09-28
ES2659648T3 (es) 2018-03-16
PT3354282T (pt) 2021-03-18

Similar Documents

Publication Publication Date Title
BR112017015614A2 (pt) produtos terapêuticos de glicano e métodos relacionados dos mesmos.
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3234152T3 (da) Svampegenommodificeringssystemer og anvendelsesfremgangsmåder
DK3180907T3 (da) Lægemiddelinformationssystem og fremgangsmåde
DK3155024T3 (da) Opholdsstrukturer og relaterede fremgangsmåder
BR112017003674A2 (pt) acopladores de onda guiada e métodos dos mesmos
BR112016016289A2 (pt) heteroaris e usos dos mesmos
DK3368655T3 (da) Forbedret proteinekspression og fremgangsmåder dertil
BR112018005409A2 (pt) terapêutica de glicodirecionamento.
BR112017026559A2 (pt) ceratoprótese e usos dos mesmos.
DK3334500T3 (da) Multiligand-lægemiddelskonjugater og anvendelser deraf
DK3265641T3 (da) Stigørenhed og fremgangsmåde
FI20155621A (fi) Menetelmä ja tuote
FI20155791A (fi) Tuote ja menetelmä
DK3463345T3 (da) Farmaceutiske kombinationer
KR20180084747A (ko) Galgt2 유전자 치료 방법 및 물질
BR112017015819A2 (pt) girador e colocador de produto
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf
DK3496525T3 (da) Forarbejdningsenhed
DK3386956T3 (da) Fumagillolderivater og polymorfer deraf
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
BR112017012635A2 (pt) produtos e métodos inovadores
DK3194583T3 (da) Ikke-fucosyleret protein og fremgangsmåder dermed
DK3166960T3 (da) Lav-substituerede polymyxiner og sammensætninger deraf
FI20145305A (fi) Proteiinituotteet ja menetelmät niiden valmistamiseksi

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/01/2016, OBSERVADAS AS CONDICOES LEGAIS